ELLANSÉ | New Dermal Fillers For Facial Collagen Stimulation - Ellansé

Advance your beauty goals.

Model is not an actual patient.

Lines and wrinkles are part of life. But that doesn’t mean you have to live with them. Discover how ELLANSÉ has advanced the beauty goals of men and women.

How ELLANSÉ is different

From the age of 25, the face loses around 1% of its volume per year.

There’s now a fast, safe and effective way to help your looks snap right back into shape and improve the signs of facial ageing.
01 Copy
Model is not an actual patient.

ELLANSÉ does so much more than traditional fillers

ELLANSÉ continues where other fillers leave off, inducing a safe, long-lasting improvement in skin density, firmness, elasticity, tone and texture.1
11
Model is not an actual patient.

Stimulating your body’s own ageing defences.

ELLANSÉ naturally gets your skin back into the habit of producing collagen* – rebuilding the youthful facial shape and volume that time has taken away.
02
Model is not an actual patient.

Restoring youth and enhancing form

${ item.title }

${ item.title }

${ item.text }> ${ item.cta.name }
Model is not an actual patient.

Why ELLANSÉ?

Dr. Shang-Li Lin

Find your clinic

Search your location or postcode to find a physician near you

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

Important Safety Considerations:

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.

Other potential adverse events include

- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.

- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.

- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.

- Adverse events, other than mentioned above, could occur as can be with any medical intervention.

All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Pharma Corporate Safety Group: quality@sinclairpharma.com